
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) stock is trading higher on Thursday, with a session volume of 21.60 million compared to the average volume of 4.9 million, as per data from Benzinga Pro.
The company announced new findings demonstrating that its lead drug candidate, Telomir-1, significantly decreases the viability of aggressive triple-negative breast cancer (TNBC) cells – a highly invasive form of breast cancer.